Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

COVID-19 mitigation efforts significantly decrease influenza activity

The mitigation strategies implemented to curb the spread of COVID-19 appears to reduce the transmission of influenza in the United States, Australia, Chile, and South Africa. These strategies may augment influenza vaccines, especially for high-risk populations during the seasonal influenza transmission.

21 Sep 2020

BU researchers find how SARS-CoV-2 infection may drive deadly lung inflammation

Responding to the COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2, requires models that can duplicate disease development in humans, identify potential targets and enable drug testing.

21 Sep 2020

Flu vaccine does not increase a person's COVID-19 risk, finds study

A new Cleveland Clinic study has found that receiving the influenza vaccine does not increase a person's risk for contracting COVID-19 or worsen associated morbidity or mortality.

21 Sep 2020

Using computer simulations to examine personalized mechanical ventilation of COVID-19 patients

Initial clinical guidelines for mechanical ventilation of COVID-19 patients suggested following standard approaches used in the treatment of acute respiratory distress syndrome (ARDS), which is characterized by rapid onset of widespread inflammation in the lungs.

21 Sep 2020

CDC updates coronavirus guidelines to recognize airborne spread

Early on in the pandemic, it was thought that the virus was only spread via respiratory droplets. However, scientific research soon showed it also to be an airborne virus. Now, the U.S. Centers for Disease Control and Prevention (CDC) has updated its guideline, acknowledging that the virus can hang in the air, fueling its spread.

21 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

A team of researchers from Aix-Marseille Univ, IHU-Méditerranée Infection, Institut Paoli Calmettes and Laboratoire d’Immunologie, Marseille, France, conducted experiments to determine if SARS-CoV-2 can affect the myeloid compartment or infect monocytes and macrophages.

20 Sep 2020

Researchers try and pop SARS-CoV-2 with an AFM tip - virion surprisingly resilient

Researchers at Semmelweis University and the National Public Health Center in Hungary have conducted an imaging study showing that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for coronavirus disease 2019 (COVID-19), is a highly dynamic and resilient virus

20 Sep 2020

Novel sequencing method could be useful for COVID-19 research

Researchers at the University of Chicago and the Cleveland Clinic have presented a novel single-cell RNA sequencing method that could be a useful application for research into the current coronavirus disease 2019 (COVID-19) pandemic.

20 Sep 2020

A novel method for 3D printing of milk-based products

Researchers from the Singapore University of Technology and Design (SUTD) developed a method to perform direct ink writing (DIW) 3D printing of milk-based products at room temperature, while maintaining its temperature sensitive nutrients.

19 Sep 2020

UM receives $33.4 million for development and clinical trials of opioid vaccines

The National Institutes of Health has awarded the University of Montana a five-year, $33.4 million award for the development and clinical trials of opioid vaccines. It is the largest such award in University history.

19 Sep 2020

Study examines performance of fabrics for home-made masks against the spread of COVID-19

Studies indicate that homemade masks help combat the spread of viruses like COVID-19 when combined with frequent hand-washing and physical distancing.

19 Sep 2020

Ineffective immune responses may be responsible for COVID-19 mortality rates in men and the elderly

News-Medical speaks to Dr. Nicole Lieberman about her latest research that discovered delayed immune responses may affect COVID-19 mortality rates.

18 Sep 2020

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

A new study published on the preprint server bioRxiv* in September 2020 reports on a Moloney murine leukemia virus (MLV) platform that produces VLPs expressing the important spike antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Sep 2020

Study: 90-minute COVID-19 test has high sensitivity and specificity

A 90-minute COVID-19 test has been shown to have over 94 per cent sensitivity, and 100 per cent specificity in a new study.

18 Sep 2020

Animal data supports efficacy of baricitinib vs SARS-COV-2

The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

LOX-1-immature neutrophils may help identify COVID-19 patients at risk of thrombosis complication

To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.

17 Sep 2020

Ceftazidime flagged as a potential inhibitor of the SARS-COV-2 virus

After screening more than 3,500 FDA-approved drugs and small molecules, researchers at the Chinese Academy of Sciences found that ceftazidime, an antibiotic approved for use in treating pneumonia, binds to the receptors that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to in human cells.

17 Sep 2020

Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

A recent study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University and published on the preprint server bioRxiv in September 2020 shows that a combination of neutralizing antibodies with intact Fc effector function can effectively reduce the viral load and prevent infection.

17 Sep 2020